1700011M02Rik Inhibitors
Chemical inhibitors of 1700011M02Rik employ a variety of molecular mechanisms to attenuate the function of this protein by interfacing with different signaling pathways and kinase activities. For instance, Staurosporine acts as a broad-spectrum kinase inhibitor, impacting numerous phosphorylation-dependent processes that can affect the activity of 1700011M02Rik. Another inhibitor, Bisindolylmaleimide I, specifically targets protein kinase C, which can disrupt the phosphorylation and, consequently, the activity of proteins that are part of the same signaling network as 1700011M02Rik. LY294002 and Wortmannin, both selective for phosphoinositide 3-kinases, can reduce the activity of 1700011M02Rik by diminishing the phosphorylation of proteins within the PI3K/Akt pathway, which plays a crucial role in regulating a multitude of cellular functions.
In addition to these, PD98059 and U0126 inhibit mitogen-activated protein kinase kinase, leading to a reduction in ERK pathway signaling that can affect the function of 1700011M02Rik, assuming it is associated with this pathway. SB203580 specifically inhibits p38 MAP kinase, which might alter the activity of 1700011M02Rik by affecting downstream proteins. SP600125's inhibition of c-Jun N-terminal kinase can similarly result in decreased activity of proteins regulated by JNK signaling, which can alter the functionality of 1700011M02Rik if it is a downstream target. Rapamycin, targeting mTOR, can also reduce the activity of proteins in the mTOR signaling pathway, which may include 1700011M02Rik. Additionally, Src family kinases, targeted by Dasatinib and PP2, and the Rho-associated protein kinase, targeted by Y-27632, play critical roles in various signaling pathways and cytoskeletal dynamics, the inhibition of which can affect the functional state of 1700011M02Rik.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases. Inhibition of these kinases can lead to reduced phosphorylation and activation of various downstream proteins, including 1700011M02Rik, thereby inhibiting its function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I specifically inhibits protein kinase C (PKC). PKC is involved in a multitude of cellular signaling pathways, and by inhibiting PKC, the phosphorylation state and activity of proteins downstream or within the same pathway as 1700011M02Rik can be inhibited. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a selective inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 can decrease the phosphorylation of proteins within the PI3K/Akt signaling pathway, a pathway that may regulate the activity of 1700011M02Rik, thereby inhibiting its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K. It functions similarly to LY294002 by blocking the PI3K/Akt pathway, which can lead to a decrease in the activity of proteins regulated by this pathway, potentially including 1700011M02Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases (ERK). By inhibiting MEK, PD98059 can decrease ERK pathway signaling, potentially leading to a reduction in activity of proteins regulated by this pathway, including 1700011M02Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 also inhibits MEK1/2, leading to suppression of the MEK/ERK signaling pathway. The inhibition of this pathway can reduce the functional activity of proteins that are regulated by or associated with ERK, which might include 1700011M02Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. Inhibition of p38 MAPK can decrease the activity of downstream proteins that rely on p38 MAPK for activation or stability, thus potentially inhibiting the function of 1700011M02Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which may reduce the activity of proteins that are regulated by JNK signaling. By inhibiting JNK, SP600125 can potentially inhibit the function of proteins that are downstream of or regulated by this pathway, which may include 1700011M02Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR). Inhibition of mTOR can reduce the activity of downstream proteins that are part of the mTOR signaling pathway, potentially leading to the functional inhibition of 1700011M02Rik if it is regulated by this pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Src family kinases. By inhibiting Src kinase activity, Dasatinib can decrease phosphorylation of Src substrates, which might reduce the activity of proteins that interact with or are downstream of Src kinases, potentially including 1700011M02Rik. | ||||||